Author

M. Kahn

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1

Frequent Co-Authors

A. August· 1 shared A. H. Bild· 1 shared A. Nath· 1 shared A. Tang· 1 shared B. Imbhiaka· 1 shared D. W. Buccholz· 1 shared E. Morrisey· 1 shared F. Chi· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

A. August

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Reprogramming of 3D chromatin domains by antagonizing the β-catenin/CBP interaction attenuates insulin signaling in pancreatic cancer

Y. Zhou, T. Li, Z. He, L. Choppavarapu, X. Hu, G. Leone, M. Kahn, V. X. Jin

This study shows that inhibiting β-catenin/CBP interaction with ICG-001 alters 3D chromatin structure in pancreatic cancer, affecting insulin signaling and promoting tumor growth.

bioRxiv · Nov 10, 2023Cancer Biology

SARS-CoV-2 infection of olfactory epithelial cells and neurons drives acute lung injury and lethal COVID-19 in mice

A. Tang, D. W. Buccholz, K. Szigety, B. Imbhiaka, S. Gao, M. Frankfurter, M. Wang, J. Yang, P. Hewins, P. Mericko-Ishizuka, N. Leu, S. Sterling, I. Monreal, J. Sahler, A. August, , M. Kahn

bioRxiv · Dec 4, 2021 · PreprintMicrobiology

A 'one-two punch' therapy strategy to target chemoresistance in estrogen receptor positive breast cancer

F. Chi, J. Liu, S. W. Brady, P. A. Cosgrove, A. Nath, J. A. McQuerry, S. Majumdar, P. J. Moos, J. T. Chang, M. Kahn, A. H. Bild

This study identifies a sequential therapy strategy using HDAC inhibitors to reverse chemotherapy-induced resistance in ER+ breast cancer by targeting cancer stem cell-like traits.

bioRxiv · Mar 12, 2020Cancer Biology